Bristol-Myers Squibb Co (BMY) Expected to Post Earnings of $0.67 Per Share

Equities analysts expect Bristol-Myers Squibb Co (NYSE:BMY) to post earnings of $0.67 per share for the current fiscal quarter, according to Zacks Investment Research. Six analysts have made estimates for Bristol-Myers Squibb’s earnings, with the lowest EPS estimate coming in at $0.63 and the highest estimate coming in at $0.70. Bristol-Myers Squibb posted earnings of $0.63 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 6.3%. The firm is expected to issue its next earnings report before the market opens on Monday, February 5th.

According to Zacks, analysts expect that Bristol-Myers Squibb will report full year earnings of $2.99 per share for the current financial year, with EPS estimates ranging from $2.96 to $3.03. For the next year, analysts expect that the company will post earnings of $3.20 per share, with EPS estimates ranging from $3.03 to $3.90. Zacks’ earnings per share averages are an average based on a survey of research firms that follow Bristol-Myers Squibb.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. Bristol-Myers Squibb’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.77 earnings per share.

BMY has been the subject of several research analyst reports. Credit Suisse Group reiterated a “hold” rating and set a $61.00 target price (up from $58.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Piper Jaffray Companies reiterated a “hold” rating and set a $60.00 target price on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Leerink Swann upped their target price on shares of Bristol-Myers Squibb from $61.00 to $72.00 and gave the company an “outperform” rating in a research note on Monday, October 23rd. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Friday. Finally, Vetr cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 target price for the company. in a research note on Thursday, September 28th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and ten have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $65.11.

In other Bristol-Myers Squibb news, Director Theodore R. Samuels II acquired 4,000 shares of the company’s stock in a transaction dated Friday, December 15th. The stock was bought at an average price of $62.30 per share, for a total transaction of $249,200.00. Following the purchase, the director now owns 22,000 shares in the company, valued at approximately $1,370,600. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total transaction of $335,172.00. Following the completion of the transaction, the executive vice president now owns 9,251 shares of the company’s stock, valued at approximately $585,033.24. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.

Several hedge funds have recently made changes to their positions in BMY. Tradewinds Capital Management LLC grew its holdings in shares of Bristol-Myers Squibb by 34.6% in the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 500 shares during the last quarter. Atlantic Trust LLC bought a new stake in shares of Bristol-Myers Squibb in the 2nd quarter worth about $111,000. Massey Quick Simon & CO. LLC grew its holdings in shares of Bristol-Myers Squibb by 523.5% in the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 1,492 shares during the last quarter. Blue Chip Partners Inc. grew its holdings in shares of Bristol-Myers Squibb by 0.7% in the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 15 shares during the last quarter. Finally, Horan Capital Advisors LLC. bought a new stake in shares of Bristol-Myers Squibb in the 3rd quarter worth about $122,000. Institutional investors own 69.74% of the company’s stock.

Bristol-Myers Squibb (BMY) opened at $62.28 on Friday. The company has a market cap of $101,930.00, a price-to-earnings ratio of 24.52, a P/E/G ratio of 2.14 and a beta of 1.18. Bristol-Myers Squibb has a one year low of $46.01 and a one year high of $66.10. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be paid a $0.40 dividend. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date is Thursday, January 4th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.57%. Bristol-Myers Squibb’s dividend payout ratio is currently 62.99%.

TRADEMARK VIOLATION WARNING: “Bristol-Myers Squibb Co (BMY) Expected to Post Earnings of $0.67 Per Share” was originally posted by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/01/20/bristol-myers-squibb-co-bmy-expected-to-post-earnings-of-0-67-per-share.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Get a free copy of the Zacks research report on Bristol-Myers Squibb (BMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply